Nexalin Technology Publishes Study on Treating Gambling Disorder and Alcohol Use Disorder.
ByAinvest
Tuesday, Nov 18, 2025 9:04 am ET1min read
NXL--
Nexalin Technology announced the publication of a peer-reviewed study in The American Journal on Addictions. The study evaluated the safety and efficacy of Nexalin's 15 milliamp neurostimulation device in a patient diagnosed with both gambling disorder and alcohol use disorder. The patient achieved complete abstinence from both after 20 outpatient treatment sessions over 10 days, with marked improvement in cognitive control and no adverse effects during a three-month follow-up period. The authors conclude that Nexalin's device is a safe and efficacious potential treatment for GD-AUD comorbidity.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet